Seelos Therapeutics (SEELQ) 10-Q 11 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	6-May-15
Document Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	APRI
Entity Registrant Name	APRICUS BIOSCIENCES, INC.
Entity Central Index Key	1017491
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		50,414,481

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets
Cash and cash equivalents	$16,156	$11,400
Accounts receivable	513	678
Restricted cash	280	290
Inventories	217	275
Prepaid expenses and other current assets	869	646
Total current assets	18,035	13,289
Property and equipment, net	1,449	1,358
Other long term assets	153	162
Total assets	19,637	14,809
Current liabilities
Notes payable	531	153
Accounts payable	880	860
Accrued expenses	5,016	4,555
Accrued compensation	550	1,112
Deferred revenue	181	226
Total current liabilities	7,158	6,906
Notes payable, net	4,294	4,626
Warrant liability	5,213	0
Deferred revenue	1,000	1,000
Other long term liabilities	302	358
Total liabilities	17,967	12,890
Commitments and contingencies
Stockholders’ equity
Preferred stock, $.001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of March 31, 2015 and December 31, 2014	0	0
Common stock, $.001 par value, 75,000,000 shares authorized, 50,414,481 and 44,330,006 issued and outstanding as of March 31, 2015 and December 31, 2014, respectively	50	44
Additional paid-in-capital	297,884	291,727
Accumulated deficit	-296,264	-289,852
Total stockholders’ equity	1,670	1,919
Total liabilities and stockholders’ equity	$19,637	$14,809

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value (USD per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock issued	0	0
Preferred stock shares outstanding	0	0
Common stock, par value (USD per share)	$0.00	$0.00
Common stock shares authorized	75,000,000	75,000,000
Common stock, issued	50,414,481	44,330,006
Common stock, outstanding	50,414,481	44,330,006

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
License fee revenue	$350	$0
Royalty revenue	88	0
Product sales	37	0
Total revenue	475	0
Cost of product sales	233	0
Gross profit	242	0
Operating expense (income)
Research and development	3,268	1,444
General and administrative	3,096	3,059
Gain on contract settlement	0	-910
Recovery loss on sale of subsidiary	0	-50
Total operating expense	6,364	3,543
Loss before other income (expense)	-6,122	-3,543
Other income (expense)
Interest expense, net	-146	-107
Other income (expense), net	-144	388
Total other income (expense)	-290	281
Net loss	($6,412)	($3,262)
Basic and diluted loss per common share (USD per share)	($0.13)	($0.09)
Weighted average common shares outstanding used for basic and diluted loss per share (shares)	47,632,760	37,872,179

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Cash Flows (Unaudited) Statement (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net loss	($6,412)	($3,262)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on contract settlement	0	910
Depreciation and amortization	74	20
Non cash interest expense	46	59
Stock-based compensation expense	289	491
Warrant liability revaluation	136	0
Recovery on loss on sale of subsidiary	0	50
Derivative liability revaluation	0	-393
Other	-12	0
Changes in operating assets and liabilities:
Accounts receivable	-165	10
Inventories	-58	28
Prepaid expenses and other current assets	223	103
Other assets	3	2
Accounts payable	-68	67
Accrued expenses	461	-203
Accrued compensation	-562	-468
Deferred revenue	-45	4,654
Other liabilities	-55	-54
Net cash used in operating activities	-6,127	-192
Cash flows from investing activities:
Purchase of fixed assets	165	355
Proceeds from sale of subsidiary	0	50
Net cash used in investing activities	-165	-305
Cash flows from financing activities:
Issuance of common stock and warrants, net of offering costs	10,957	1,641
Release (deposit) of restricted cash	-10	50
Proceeds from the exercise of stock options	83	0
Repayment of capital lease obligations	2	8
Net cash provided by financing activities	11,048	1,583
Net increase in cash and cash equivalents	4,756	1,086
Cash and cash equivalents, beginning of period	11,400	21,405
Cash and cash equivalents, end of period	16,156	22,491
Non-cash investing and financing activities:
Liability incurred in connection with February 2015 financing	88	0
Liability incurred in connection with fixed asset purchases	0	70
Retirement of restricted stock	$0	$42

Basis_of_Presentation

Basis of Presentation

3 Months Ended

Mar. 31, 2015

Accounting Policies [Abstract]

Basis of Presentation

BASIS OF PRESENTATION

Financial Statement Presentation

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2014 included in the Apricus Biosciences, Inc. and subsidiaries (the “Company”) Annual Report on Form 10-K (“Annual Report”) filed with the Securities and Exchange Commission (the “SEC”) on March 16, 2015. The accompanying financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. In the opinion of the Company’s management, all adjustments that are of a normal recurring nature and considered necessary for fair statement have been included in the accompanying condensed consolidated financial statements. Certain prior year items in the statement of cash flows have been reclassified to conform to the current year presentation. The condensed consolidated balance sheet was derived from audited financial statements, but does not include all GAAP disclosures. The unaudited condensed consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. The preparation of these unaudited condensed consolidated financial statements requires the Company to make estimates and judgments that affect the amounts reported in the financial statements and the accompanying notes. The Company’s actual results may differ from these estimates under different assumptions or conditions.

Liquidity

The accompanying unaudited condensed consolidated financial statements have been prepared on a basis that contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company had an accumulated deficit of approximately $296.3 million as of March 31, 2015, recorded a net loss of approximately $6.4 million for the three months ended March 31, 2015 and has principally been financed through the sale of its common stock and other equity securities, debt financing and up-front payments received from commercial partners for the Company’s products under development.

In February 2015, the Company entered into subscription agreements with certain purchasers pursuant to which it sold an aggregate of 6,043,955 shares of its common stock and issued warrants to purchase up to an additional 3,021,977 shares of its common stock.  Each share of common stock was sold at a price of $1.82 and included one half of a warrant to purchase a share of common stock. The warrants have an exercise price of $1.82 per share, are exercisable beginning six months and one day after the date of issuance and expire on the seventh anniversary of the date of issuance. The total net proceeds from the offering were $10.9 million after deducting expenses of approximately $0.1 million. The subscription agreements grant certain of the purchasers preemptive rights to participate in future equity issuances by the Company, subject to certain exceptions, and require that the Company obtain permission from certain of the purchasers prior to selling shares under its committed equity financing facility with Aspire Capital Fund, LLC (“Aspire Capital”).

Based upon its current operating plan, the access to additional capital under its committed equity financing facility, potential to borrow an additional amount of up to $5.0 million under its credit facility with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB”), and the $10.9 million received from the Company’s February 2015 financing, the Company believes it has sufficient cash to fund its on-going operations through the second quarter of 2016.

Based on its recurring losses, negative cash flows from operations and working capital levels, the Company will need to raise substantial additional funds to finance its operations. If the Company is unable to maintain sufficient financial resources, including by raising additional funds when needed, its business, financial condition and results of operations will be materially and adversely affected. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or debt financings may have a dilutive effect on the holdings of the Company’s existing stockholders.

Warrant Liabilities

The Company’s outstanding common stock warrants issued in connection with its February 2015 financing are classified as liabilities in the accompanying condensed consolidated balance sheets as they contain provisions that could require the Company to settle the warrants in cash. The warrants were recorded at fair value using the Black-Scholes option pricing model. The fair value of these warrants is re-measured at each financial reporting period with any changes in fair value being recognized as a component of other income (expense) in the accompanying condensed consolidated statements of operations.

Fair Value Measurements

The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Financial assets and liabilities that are measured or disclosed at fair value on a recurring basis, and are classified within the Level 3 designation include the common stock warrant liabilities. None of the Company’s non-financial assets and liabilities are recorded at fair value on a non-recurring basis.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

The following table presents the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of March 31, 2015 (in thousands):

Fair Value

Quoted  Market  Prices for Identical Assets

Significant  Other

Significant

(Level 1)

Observable Inputs

Unobservable

(Level 2)

Inputs  (Level 3)

Warrant liability related to February 2015 financing

$

5,213

—

$

—

$

5,213

The common stock warrant liabilities are recorded at fair value using the Black-Scholes option pricing model.  The following weighted-average assumptions were used in determining the fair value of the common stock warrant liabilities valued using the Black-Scholes option pricing model as of March 31, 2015:

Risk-free interest rate

1.46

%

Volatility

132.47

%

Dividend yield

—

%

Expected term

6.86 years

Weighted average fair value

$

1.72

The following table is a reconciliation for all liabilities measured at fair value using Level 3 unobservable inputs (in thousands):

Warrant liability

Balance as of December 31, 2014

$

—

Issuance of warrants in connection with February 2015 financing

5,077

Change in fair value measurement of warrant liability

136

Balance as of March 31, 2015

$

5,213

Of the inputs used to value the outstanding common stock warrant liabilities as of March 31, 2015, the most subjective input is the Company’s estimate of expected volatility.  If volatility were increased to 150%, the weighted average fair market value of the outstanding common stock warrants outstanding would increase approximately $0.2 million, or 3.4%.

Revenue Recognition

The Company generates revenues from the licensing of technology rights, the sale of products, and historically, from the performance of contract sales services. Payments received under commercial arrangements, such as the licensing of technology rights, may include non-refundable fees at the inception of the arrangements, milestone payments for specific achievements designated in the agreements, and royalties on the sale of products.

The Company recognizes revenue when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the Company’s price to the buyer is fixed or determinable; and (4) collectability is reasonably assured.

Consideration received for the Company’s license arrangements may consist of non-refundable upfront license fees, various performance or sales milestones, royalties upon sales of product, and the delivery of product and/or research services. The Company considers a variety of factors in determining the appropriate method of accounting under its license agreements, including whether the various elements can be separated and accounted for individually as separate units of accounting. Deliverables under the arrangement will be separate units of accounting, provided (i) a delivered item has value to the customer on a standalone basis; and (ii) the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the Company’s control.

Multiple element arrangements

The Company accounts for revenue arrangements with multiple elements by separating and allocating consideration according to the relative selling price of each deliverable. If an element can be separated, an amount is allocated based upon the relative selling price of each element. The Company determines the relative selling price of a separate deliverable using the price it charges other customers when it sells that product or service separately. If the product or service is not sold separately and third party pricing evidence is not available, the Company will use its best estimate of selling price.

Milestones

Revenue is recognized when earned, as evidenced by written acknowledgment from the collaborator or other persuasive evidence that the milestone has been achieved, provided that the milestone event is substantive. A milestone event is considered to be substantive if its achievability was not reasonably assured at the inception of the arrangement and the Company’s efforts led to the achievement of the milestone (or if the milestone was due upon the occurrence of a specific outcome resulting from the Company’s performance). Events for which the occurrence is either contingent solely upon the passage of time or the result of a counterparty’s performance are not considered to be milestone events. If both of these criteria are not met, the milestone payment is recognized over the remaining minimum period of the Company’s performance obligations under the arrangement, if any. The Company assesses whether a milestone is substantive at the inception of each arrangement.

License Fee Revenue

The Company defers recognition of non-refundable upfront fees if it has continuing performance obligations, without which the technology, right, product or service has no utility to the licensee separate and independent of its performance under the other elements of the applicable arrangement. Non-refundable, up-front fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the Company’s part are recognized as revenue when the license term commences and the licensed data, technology and/or compound is delivered. The specific methodology for the recognition of the revenue is determined on a case-by-case basis according to the facts and circumstances of the applicable agreement.

Product Sales Revenue

The Company has supply and manufacturing agreements with certain of its licensee partners for the manufacture and delivery of Vitaros® product. These agreements do not permit the Company’s licensee partners to return product, unless the product sold to the licensee partner is short-dated as defined in each respective license agreement. In those cases, the Company defers revenue recognition until the right of return no longer exists, which is the earlier of: (i) evidence that the product has been sold to an end customer or (ii) the right of return has expired. As such, the Company does not have a sales and returns allowance recorded as of March 31, 2015.

Beginning in 2014, the Company commenced shipment of its Vitaros® product to its licensee partners and recognized product sales revenue on certain of these shipments since the criteria for revenue recognition was met.

Royalty Revenue

The Company relies on its commercial partners to sell Vitaros® in approved markets. The Company receives royalties from licensee partners based upon the amount of sales of licensed Vitaros® product by its commercial partners. Royalty revenues are computed based on sales reported to the Company by its licensee partners on a quarterly basis and at the contractual royalty rates for each respective license agreement.

Cost of Product Sales

The Company’s cost of product sales includes direct material and manufacturing overhead associated with production. Cost of product sales is also affected by manufacturing efficiencies, allowances for scrap or expired material and additional costs related to initial production quantities of new products.

Deferred Cost of Product Sales

Deferred cost of product sales is stated at the lower of cost or net realizable value and includes product sold where title has transferred, but the criteria for revenue recognition have not been met. The Company’s deferred cost of product sales is included in prepaid expenses and other current assets in the condensed consolidated balance sheets.

Loss per Common Share

Basic and diluted net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding for the respective period, without consideration of common stock equivalents as they would have an anti-dilutive effect on per share amounts.

The following securities that could potentially decrease net loss per share in the future are not included in the determination of diluted loss per share as they are anti-dilutive and are as follows:

Three Months Ended

March 31,

2015

2014

Outstanding stock options

4,592,562

3,684,745

Outstanding warrants

9,881,659

6,185,492

Stock-Based Compensation

The estimated grant date fair value of stock options granted to employees and directors is calculated based upon the closing stock price of the Company’s common stock on the date of the grant and recognized as stock-based compensation expense over the expected service period. The Company estimates the fair value of each option award on the date of grant using the Black-Scholes option pricing model.

The Company also issues performance-based shares which represent a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, the Company reassesses the probability of the achievement of such corporate performance goals and adjusts expense as necessary.

The following table presents the weighted average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option-pricing model, as well as the resulting weighted average fair values:

Three Months Ended

March 31,

2015

2014

Risk-free interest rate

1.39% - 1.67%

1.58% - 1.96%

Volatility

81.13%- 101.54%

80.75

%

Dividend yield

—

%

—

%

Expected term

5.25- 6.08 years

5.25- 6.08 years

Forfeiture rate

11.54

%

3.6

%

Weighted average fair value

$

1.05

$

1.48

The Company granted approximately 1.2 million and 1.3 million shares during the three months ended March 31, 2015 and 2014, respectively. During the three months ended March 31, 2015, approximately 40,000 shares were exercised and approximately 0.5 million shares were forfeited.

The following table summarizes the total stock-based compensation expense resulting from share-based awards recorded in the Company’s condensed consolidated statements of operations (in thousands):

Three Months Ended

March 31,

2015

2014

Research and development

$

30

$

89

General and administrative

259

402

Total

$

289

$

491

Segment Information

The Company operates under one segment which develops pharmaceutical products.

Recent Accounting Pronouncements

In November 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-16, Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share is More Akin to Debt or to Equity. This update clarifies how current guidance should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. In addition, it clarifies that in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (that is, the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weight those terms and features. The effects of initially adopting the new standard should be applied on a modified retrospective basis to existing hybrid financial instruments issued in a form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted. The Company is currently in the process of evaluating whether the adoption of this update will have a material effect on its condensed consolidated financial statements and related disclosures.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments in this update will require management to assess, at each annual and interim reporting period, the entity’s ability to continue as a going concern and, if management identifies conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued, to disclose in the notes to the entity’s financial statements the principal conditions or events that raised substantial doubt about the entity’s ability to continue as a going concern, management’s evaluation of their significance, and management’s plans that alleviated or are intended to alleviate substantial doubt about the entity’s ability to continue as a going concern. This new standard is effective for annual periods ending after December 15, 2016 and early application is permitted. The Company is currently in the process of evaluating whether the adoption of this update will have a material effect on its condensed consolidated financial statements and related disclosures.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This pronouncement is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the effect that this pronouncement will have on its financial statements and related disclosures.

Vitaros_Licensing_Agreements

Vitaros Licensing Agreements	3 Months Ended
	Mar. 31, 2015
Disclosure - Licensing and Research and Development Agreements [Abstract]
Vitaros Licensing Agreements	VITAROS® LICENSING AGREEMENTS
	Abbott Laboratories Limited
	In January 2012, the Company entered into a license agreement with Abbott Laboratories Limited (“Abbott”), granting Abbott the exclusive rights to commercialize Vitaros® for the treatment of ED in Canada. The product was approved for the treatment of ED by Health Canada in late 2010. To date, the Company has received an upfront payment of $2.5 million. The Company is eligible to receive up to an additional $13.2 million, including a regulatory milestone payment of $0.2 million related to approval of the room temperature formulation of Vitaros® and $13.0 million in aggregate sales milestones. Additionally, the Company is eligible to receive tiered double-digit royalties on Abbott’s sales of the product.
	Bracco SpA
	In December 2010, the Company entered into a license agreement with Bracco SpA (“Bracco”), granting Bracco the exclusive rights to commercialize Vitaros® for the treatment of ED in Italy. The product was approved for the treatment of ED in Italy in November 2013. To date, the Company has received $1.3 million, including an upfront payment and a regulatory milestone payment related to the approval of Vitaros® in Italy. The Company is eligible to receive up to an additional €4.5 million ($4.9 million as of March 31, 2015) in aggregate sales milestones, plus tiered double-digit royalties on Bracco’s sales of the product.
	Hexal AG, an affiliate within the Sandoz Division of the Novartis Group of Companies
	The Company has entered into three license agreements with Hexal AG, an affiliate within the Sandoz Division of the Novartis Group of Companies (“Sandoz”), in February 2012, December 2013 and February 2015. The agreements are collectively referred to herein as the “Sandoz Agreements”. The first agreement granted Sandoz the exclusive rights to commercialize Vitaros® for the treatment of ED in Germany. The second agreement extended the exclusive license grant to the following countries: Austria, Belgium, Denmark, Finland, Iceland, Luxemburg, the Netherlands, Norway, Sweden and Switzerland (the “Expanded Territory”). The third agreement further extended the exclusive license grant to the following additional countries: Malaysia, Indonesia, the Philippines, Thailand, Taiwan, Vietnam, Hong Kong and Singapore (the “Expanded APAC Territory”). In June 2014, the Company also entered into a Manufacturing and Supply Agreement with Sandoz whereby the Company or its contract manufacturer will manufacture Vitaros® product and supply the product to Sandoz on a cost plus basis.
	The product has been approved for the treatment of ED in Germany, the Netherlands, Sweden, Belgium and Luxembourg. The Company filed a marketing application in Switzerland with Swissmedic, the Swiss Agency for Therapeutic Products, for Vitaros® for the treatment of ED and is awaiting regulatory comments from Swissmedic. To date, Sandoz has launched Vitaros® in Germany, Belgium and Sweden.
	The Company has received a total of $4.3 million to date under the Sandoz Agreements, which includes: (a) upfront payments totaling $3.0 million for Germany, the Expanded Territory and the Expanded APAC Territory; (b) a regulatory milestone payment of $0.3 million related to the approval of Vitaros® in Germany; and (c) launch milestones totaling $1.0 million related to the launch of the product in Sweden and Belgium in August 2014 and November 2014, respectively.
	The Company is eligible to receive up to an additional $47.1 million under the Sandoz Agreements, which includes: (a) up to €0.3 million ($0.3 million as of March 31, 2015) in regulatory milestones related to approval of the product in the Expanded APAC Territory and approval of the room temperature formulation of Vitaros®; (b) up to $1.5 million in launch milestones related to the launch of the product in Switzerland and the room temperature formulation of Vitaros®; and (c) up to €41.8 million ($45.3 million as of March 31, 2015) in aggregate sales milestones. Additionally, the Company is eligible to receive tiered double-digit royalties on Sandoz’ sales of the product.
	The Company recorded $2.0 million of deferred revenue for the upfront payment received from Sandoz for the Expanded Territory because Sandoz was entitled to a $2.0 million refund if certain regulatory and manufacturing conditions were not met. In December 2014, the Company met the manufacturing requirement and recognized $1.0 million of the upfront payment as license fee revenue. The results of the regulatory condition will be determined by December 2016.
	Laboratoires Majorelle
	In November 2013, the Company entered into a license agreement with Laboratoires Majorelle (“Majorelle”), granting Majorelle the exclusive rights to market Vitaros® for the treatment of ED in France, Monaco and certain countries in Africa. To date, the product has been approved for the treatment of ED in France.
	In December 2013, in a related negotiation, Majorelle agreed to make severance payments to certain former employees of Scomedica SAS, NexMed Europe SAS and NexMed Pharma SAS (the “French Subsidiaries”) for an aggregate amount of approximately $2.0 million on behalf of the Company. In September 2014, the Company entered into a Manufacturing and Supply Agreement with Majorelle whereby the Company or its contract manufacturer will manufacture Vitaros® product and supply the product to Majorelle on a cost plus basis. During the first quarter of 2015, Groupe Parima began manufacturing product for Majorelle under its own manufacturing and supply agreement.
	The Company concluded that the fair value of the Vitaros® license granted was equal to $4.0 million or the sum of the $1.8 million upfront payment received, the $0.2 million payment received for National Phase approval in France, and the $2.0 million paid by Majorelle on behalf of the Company. During the second quarter of 2014, upon withdrawal of the Works Council Claim in June 2014, the Company recognized $3.0 million of the $4.0 million Vitaros® license fair value as license fee revenue in its statement of operations. During the third quarter of 2014, the Company met the remaining contractual condition to deliver a specified amount of Vitaros® and therefore, the remaining $1.0 million of deferred revenue that had previously been deferred was recognized as license fee revenue in the Company’s condensed consolidated statement of operations.
	To date, the Company has received $2.0 million under the license agreement, including an upfront payment and a regulatory milestone payment related to the approval of Vitaros® in France. The Company is eligible to receive up to an additional $18.8 million, including a regulatory milestone payment of $2.0 million related to approval of the room temperature formulation of Vitaros® and up to €15.5 million ($16.8 million as of March 31, 2015) in aggregate sales milestones. Additionally, the Company is eligible to receive tiered double-digit royalties on Majorelle’s sales of the product.
	Recordati Ireland Ltd.
	In February 2014, the Company entered into a license agreement with Recordati Ireland Ltd. (“Recordati”), granting Recordati the exclusive rights to market Vitaros® for the treatment of ED in Spain, Ireland, Portugal, Greece, Cyprus, the CEE Countries (Central and Eastern Europe), Russia and the other CIS Countries (former Soviet Republics), Ukraine, Georgia, Turkey and certain countries in Africa. The product has been approved for the treatment of ED in Ireland and Spain. In June 2014, the Company entered into a Manufacturing and Supply Agreement with Recordati whereby the Company or its contract manufacturer will manufacture Vitaros® product and supply the product to Recordati on a cost plus basis. Recordati launched Vitaros® in Spain in May 2015.
	To date, the Company has received an upfront payment of $2.5 million, which was recorded as deferred revenue. Upon execution of the manufacturing and supply agreement in June 2014, the Company recorded the deferred revenue as license fee revenue of $2.5 million. The Company is eligible to receive up to an additional $38.5 million, including up to €1.0 million ($1.1 million as of March 31, 2015) in launch milestones related to the launch of the product in Russia and Turkey and up to €34.5 million ($37.4 million as of March 31, 2015) in aggregate sales milestones. Additionally, the Company is eligible to receive tiered double-digit royalties on Recordati’s sales of the product.
	Takeda Pharmaceuticals International GmbH
	In September 2012, the Company entered into a license agreement with Takeda Pharmaceuticals International GmbH (“Takeda”), granting Takeda the exclusive right to market Vitaros® for the treatment of ED in the United Kingdom. In September 2013, the Company entered into a Manufacturing and Supply Agreement with Takeda whereby the Company or its contract manufacturer will manufacture Vitaros® product and supply the product to Takeda. The product has been approved for the treatment of ED in the UK and Takeda launched Vitaros® in the UK in June 2014.
	To date, the Company has received an upfront payment of $1.0 million. The Company is eligible to receive up to an additional €33.9 million ($36.8 million as of March 31, 2015), including a regulatory milestone payment of €0.4 million ($0.4 million as of March 31, 2015) related to approval of the room temperature formulation of Vitaros and up to €33.5 million ($36.3 million as of March 31, 2015) in aggregate sales milestones. Additionally, the Company is eligible to receive tiered double-digit royalties on Takeda’s sales of the product.
	Actavis plc
	In 2009, Warner Chilcott Company, Inc., now a subsidiary of Actavis plc, acquired the commercial rights to Vitaros® in the United States. To date, the Company has received $2.5 million in upfront payments and is eligible to receive up to an additional $2.5 million upon receipt of an NDA approval from the FDA.

InLicensing_Agreement

In-Licensing Agreement	3 Months Ended
	Mar. 31, 2015
In-Licensing Agreement [Abstract]
In-Licensing Agreement	IN-LICENSING AGREEMENT
	On October 17, 2014, the Company entered into a license agreement and stock issuance agreement with Forendo Pharma Ltd. (“Forendo”), under which the Company was granted exclusive rights in the United States to develop and commercialize fispemifene, a tissue-specific SERM designed to treat sexual dysfunction in men diagnosed with secondary hypogonadism, as well as chronic prostatitis and lower urinary tract symptoms in men.
	In exchange for the license, the Company issued to Forendo approximately 3.6 million shares of common stock with a value of $5.9 million based on the Company’s closing stock price on the date of the agreement and made an upfront cash payment of $5.0 million. Additionally, the Company may be obligated to pay Forendo up to $45.0 million based on completion of certain regulatory milestones, up to $260.0 million in sales milestones, plus tiered double-digit royalties based on its sales of the product in the United States.
	As part of the agreement, the Company paid Forendo $2.5 million in April 2015. Since the agreement was not terminable prior to payment, the payment was considered deferred consideration and was recorded as a liability as of March 31, 2015 and December 31, 2014.
	The Company recognized research and development expense of $13.6 million upon the completion of the transaction in December 2014. The $13.6 million is the sum of the following: $5.0 million upfront payment made in October 2014; $5.9 million in common stock issued to Forendo; the $2.5 million cash consideration paid in April 2015, and transaction costs of $0.2 million.

Other_Financial_Information

Other Financial Information	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Financial Information	OTHER FINANCIAL INFORMATION
	Inventory
	Inventory is comprised of the following (in thousands):
		March 31,		December 31, 2014
		2015
	Raw materials	$	105	$	106
	Work in process	112		169
	Inventory	$	217	$	275
	Accrued Expenses
	Accrued expenses are comprised of the following (in thousands):
		March 31,		December 31, 2014
		2015
	Deferred consideration to Forendo (Note 3)	$	2,500	$	2,500
	Outside research and development services	984		838
	Professional fees	991		625
	Deferred compensation	180		176
	Environmental remediation	119		126
	Other	242		290
		$	5,016	$	4,555
	Other Long Term Liabilities
	Other long term liabilities are comprised of the following (in thousands):
		March 31,		31-Dec-14
		2015
	Deferred compensation	$	268	$	312
	Deferred rent	31		41
	Capital lease payable	3		5
		$	302	$	358
	In 2002, the Company entered into an employment agreement with Y. Joseph Mo, Ph.D., pursuant to which Dr. Mo served as the Company’s Chief Executive Officer and President. Under the employment agreement, Dr. Mo was entitled to severance, payable monthly for 180 months, upon termination of his employment. Dr. Mo’s employment was terminated in December 2005. In addition to the long-term portion above, the Company had a balance of $0.2 million classified as short-term deferred severance compensation as of March 31, 2015 and December 31, 2014.
	Gain on Contract Settlement
	The $0.9 million gain on contract settlement recorded during 2014 represents the fair value of 388,888 escrowed shares of common stock that were returned to the Company in connection with a settlement with former managers of the French Subsidiaries. These shares were restored as authorized, unissued common stock in March 2014.

Debt

Debt	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt	DEBT
	Credit Facility
	On October 17, 2014 (the “closing date”), the Company entered into a loan and security agreement (the “credit facility”) with Oxford and SVB (Oxford and SVB are referred to together as the “lenders”), pursuant to which the lenders agreed to make term loans totaling up to $10.0 million available to the Company. The proceeds from these loans are designated to pay off existing indebtedness and for working capital and general business purposes. The first $5.0 million term loan was funded on the closing date of the credit facility. A second term loan of up to a principal amount of $5.0 million may be funded at the Company’s request, subject to certain conditions. Pursuant to the terms of the credit facility, the lenders have a senior-secured lien on all of the Company’s current and future assets, other than intellectual property. The lenders have the right to declare the loan immediately due and payable in an event of default under the credit facility, which includes, among other things, a material adverse change in the Company’s business, operations, or financial condition or a material impairment in the prospect of repayment of the loan. As of March 31, 2015, the Company was in compliance with all covenants under the credit facility.
	The first term loan bears interest at an annual rate of 7.95%. The repayment schedule provides for interest-only payments in arrears for the first 12 months followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date, which is October 1, 2018. The Company has the option to prepay the outstanding balance of the term loan in full prior to the maturity date, subject to a prepayment fee of up to 3%. Upon repayment of each term loan, the Company is also required to make a final payment to the lenders equal to 6.00% of the original principal amount of each term loan. This final payment is being accreted over the life of the credit facility using the effective interest method.
	On the closing date of the credit facility, the Company issued warrants to purchase up to 193,798 shares of common stock at an exercise price of $1.29 per share to Oxford and SVB. The warrants expire ten years from the date of issuance. The initial fair value of the warrants was recorded as a discount to the principal balance and is being amortized over the life of the credit facility using the effective interest method.
	The Company’s notes payable balance consisted of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Notes payable, principal	$	5,000		$	5,000
	Add: accretion of final payment fee	40			16
	Less: unamortized debt discount	(215		)	(237		)
		4,825			4,779
	Less: current portion of notes payable, net	(531		)	(153		)
		$	4,294		$	4,626
	The debt issuance costs, accretion of the final payment and amortization of the warrants are included in interest expense in the Company’s condensed consolidated financial statements. The Company recognized interest expense related to the credit facility of $0.1 million during the three months ended March 31, 2015.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Stockholder's Equity	STOCKHOLDERS' EQUITY
	Common Stock Offerings
	February 2015 Financing
	In February 2015, the Company entered into subscription agreements with certain purchasers pursuant to which it sold an aggregate of 6,043,955 shares of its common stock and issued warrants to purchase up to an additional 3,021,977 shares of its common stock.  Each share of common stock was sold at $1.82 and included one half of a warrant to purchase a share of common stock. The warrants have an exercise price of $1.82 per share, are exercisable beginning six months and one day after the date of issuance and expire on the seventh anniversary of the date of issuance. The total net proceeds from the offering were $10.9 million after deducting expenses of approximately $0.1 million. The subscription agreements grant certain of the purchasers preemptive rights to participate in future equity issuances by the Company, subject to certain exceptions, and require that the Company obtain permission from certain of the purchasers of the subscription agreements prior to selling shares under its committed equity financing facility with Aspire Capital.
	Warrants
	A summary of warrant activity during the three months ended March 31, 2015 is as follows:
		Common Shares		Weighted			Weighted
		Issuable upon		Average			Average
		Exercise		Exercise			Remaining
				Price			Contractual
							Life (in years)
	Outstanding at December 31, 2014	6,859,682		$	3.83		2.7
	Issued	3,021,977		1.82
	Exercised	—		—
	Cancelled	—		—
	Outstanding at March 31, 2015	9,881,659		3.21			3.8
	Exercisable at March 31, 2015	6,859,682		$	3.83		2.4
	In connection with the credit facility entered into in October 2014, the Company issued warrants to the lenders to purchase up to 193,798 shares of common stock at an exercise price of $1.29 per share. The warrants expire ten years from the date of issuance. The Company also issued warrants to its former convertible note holders to purchase up to an aggregate of 480,392 shares of common stock at an exercise price of $2.55 per share. The warrants are exercisable through December 31, 2015.
	In connection with the February 2015 financing, the Company issued warrants to purchase up to 3,021,977 shares of its common stock at an exercise price of $1.82 per share. These warrants are exercisable through February 13, 2022. The initial $5.1 million fair value of the warrants on the transaction date was determined using the Black-Scholes option pricing model and was recorded as the initial carrying value of the common stock warrant liability. The fair value of these warrants is remeasured at each financial reporting period with any changes in fair value recognized as a component of other income (expense) in the accompanying condensed consolidated statements of operations. As of March 31, 2015, the fair value of the warrants was $5.2 million.
	The following table shows the number of outstanding warrants by exercise price and date of expiration as of March 31, 2015:
	Shares Issuable Upon Exercise		Exercise Price			Expiration Date
	716,356		$	2.27		Oct-15
	480,392		$	2.55		Dec-15
	2,469,136		$	5.25		Feb-17
	3,000,000		$	3.4		May-18
	3,021,977		$	1.82		Feb-22
	193,798		$	1.29		Jan-24
	9,881,659

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES
	The Company is a party to certain litigation that is either judged to be not material or that arises in the ordinary course of business from time to time. The Company intends to vigorously defend its interests in these matters. The Company expects that the resolution of these matters will not have a material adverse effect on its business, financial condition or results of operations. However, due to the uncertainties inherent in litigation, no assurance can be given as to the outcome of these proceedings.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Financial Statement Presentation	Financial Statement Presentation
	The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2014 included in the Apricus Biosciences, Inc. and subsidiaries (the “Company”) Annual Report on Form 10-K (“Annual Report”) filed with the Securities and Exchange Commission (the “SEC”) on March 16, 2015. The accompanying financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. In the opinion of the Company’s management, all adjustments that are of a normal recurring nature and considered necessary for fair statement have been included in the accompanying condensed consolidated financial statements. Certain prior year items in the statement of cash flows have been reclassified to conform to the current year presentation. The condensed consolidated balance sheet was derived from audited financial statements, but does not include all GAAP disclosures. The unaudited condensed consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. The preparation of these unaudited condensed consolidated financial statements requires the Company to make estimates and judgments that affect the amounts reported in the financial statements and the accompanying notes. The Company’s actual results may differ from these estimates under different assumptions or conditions.
Liquidity	Liquidity
	The accompanying unaudited condensed consolidated financial statements have been prepared on a basis that contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company had an accumulated deficit of approximately $296.3 million as of March 31, 2015, recorded a net loss of approximately $6.4 million for the three months ended March 31, 2015 and has principally been financed through the sale of its common stock and other equity securities, debt financing and up-front payments received from commercial partners for the Company’s products under development.
	In February 2015, the Company entered into subscription agreements with certain purchasers pursuant to which it sold an aggregate of 6,043,955 shares of its common stock and issued warrants to purchase up to an additional 3,021,977 shares of its common stock.  Each share of common stock was sold at a price of $1.82 and included one half of a warrant to purchase a share of common stock. The warrants have an exercise price of $1.82 per share, are exercisable beginning six months and one day after the date of issuance and expire on the seventh anniversary of the date of issuance. The total net proceeds from the offering were $10.9 million after deducting expenses of approximately $0.1 million. The subscription agreements grant certain of the purchasers preemptive rights to participate in future equity issuances by the Company, subject to certain exceptions, and require that the Company obtain permission from certain of the purchasers prior to selling shares under its committed equity financing facility with Aspire Capital Fund, LLC (“Aspire Capital”).
	Based upon its current operating plan, the access to additional capital under its committed equity financing facility, potential to borrow an additional amount of up to $5.0 million under its credit facility with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB”), and the $10.9 million received from the Company’s February 2015 financing, the Company believes it has sufficient cash to fund its on-going operations through the second quarter of 2016.
	Based on its recurring losses, negative cash flows from operations and working capital levels, the Company will need to raise substantial additional funds to finance its operations. If the Company is unable to maintain sufficient financial resources, including by raising additional funds when needed, its business, financial condition and results of operations will be materially and adversely affected. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or debt financings may have a dilutive effect on the holdings of the Company’s existing stockholders.
Fair Value Measurement	The warrants were recorded at fair value using the Black-Scholes option pricing model. The fair value of these warrants is re-measured at each financial reporting period with any changes in fair value being recognized as a component of other income (expense) in the accompanying condensed consolidated statements of operations.
	Fair Value Measurements
	The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Financial assets and liabilities that are measured or disclosed at fair value on a recurring basis, and are classified within the Level 3 designation include the common stock warrant liabilities. None of the Company’s non-financial assets and liabilities are recorded at fair value on a non-recurring basis.
	In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.
Revenue Recognition	Revenue Recognition
	The Company generates revenues from the licensing of technology rights, the sale of products, and historically, from the performance of contract sales services. Payments received under commercial arrangements, such as the licensing of technology rights, may include non-refundable fees at the inception of the arrangements, milestone payments for specific achievements designated in the agreements, and royalties on the sale of products.
	The Company recognizes revenue when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the Company’s price to the buyer is fixed or determinable; and (4) collectability is reasonably assured.
	Consideration received for the Company’s license arrangements may consist of non-refundable upfront license fees, various performance or sales milestones, royalties upon sales of product, and the delivery of product and/or research services. The Company considers a variety of factors in determining the appropriate method of accounting under its license agreements, including whether the various elements can be separated and accounted for individually as separate units of accounting. Deliverables under the arrangement will be separate units of accounting, provided (i) a delivered item has value to the customer on a standalone basis; and (ii) the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the Company’s control.
	Multiple element arrangements
	The Company accounts for revenue arrangements with multiple elements by separating and allocating consideration according to the relative selling price of each deliverable. If an element can be separated, an amount is allocated based upon the relative selling price of each element. The Company determines the relative selling price of a separate deliverable using the price it charges other customers when it sells that product or service separately. If the product or service is not sold separately and third party pricing evidence is not available, the Company will use its best estimate of selling price.
	Milestones
	Revenue is recognized when earned, as evidenced by written acknowledgment from the collaborator or other persuasive evidence that the milestone has been achieved, provided that the milestone event is substantive. A milestone event is considered to be substantive if its achievability was not reasonably assured at the inception of the arrangement and the Company’s efforts led to the achievement of the milestone (or if the milestone was due upon the occurrence of a specific outcome resulting from the Company’s performance). Events for which the occurrence is either contingent solely upon the passage of time or the result of a counterparty’s performance are not considered to be milestone events. If both of these criteria are not met, the milestone payment is recognized over the remaining minimum period of the Company’s performance obligations under the arrangement, if any. The Company assesses whether a milestone is substantive at the inception of each arrangement.
	License Fee Revenue
	The Company defers recognition of non-refundable upfront fees if it has continuing performance obligations, without which the technology, right, product or service has no utility to the licensee separate and independent of its performance under the other elements of the applicable arrangement. Non-refundable, up-front fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the Company’s part are recognized as revenue when the license term commences and the licensed data, technology and/or compound is delivered. The specific methodology for the recognition of the revenue is determined on a case-by-case basis according to the facts and circumstances of the applicable agreement.
	Product Sales Revenue
	The Company has supply and manufacturing agreements with certain of its licensee partners for the manufacture and delivery of Vitaros® product. These agreements do not permit the Company’s licensee partners to return product, unless the product sold to the licensee partner is short-dated as defined in each respective license agreement. In those cases, the Company defers revenue recognition until the right of return no longer exists, which is the earlier of: (i) evidence that the product has been sold to an end customer or (ii) the right of return has expired. As such, the Company does not have a sales and returns allowance recorded as of March 31, 2015.
	Beginning in 2014, the Company commenced shipment of its Vitaros® product to its licensee partners and recognized product sales revenue on certain of these shipments since the criteria for revenue recognition was met.
	Royalty Revenue
	The Company relies on its commercial partners to sell Vitaros® in approved markets. The Company receives royalties from licensee partners based upon the amount of sales of licensed Vitaros® product by its commercial partners. Royalty revenues are computed based on sales reported to the Company by its licensee partners on a quarterly basis and at the contractual royalty rates for each respective license agreement.
Cost of Product Sales and Deferred Cost of Product Sales	Cost of Product Sales
	The Company’s cost of product sales includes direct material and manufacturing overhead associated with production. Cost of product sales is also affected by manufacturing efficiencies, allowances for scrap or expired material and additional costs related to initial production quantities of new products.
	Deferred Cost of Product Sales
	Deferred cost of product sales is stated at the lower of cost or net realizable value and includes product sold where title has transferred, but the criteria for revenue recognition have not been met. The Company’s deferred cost of product sales is included in prepaid expenses and other current assets in the condensed consolidated balance sheets.
Loss Per Common Share	Loss per Common Share
	Basic and diluted net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding for the respective period, without consideration of common stock equivalents as they would have an anti-dilutive effect on per share amounts.
Stock-Based Compensation	Stock-Based Compensation
	The estimated grant date fair value of stock options granted to employees and directors is calculated based upon the closing stock price of the Company’s common stock on the date of the grant and recognized as stock-based compensation expense over the expected service period. The Company estimates the fair value of each option award on the date of grant using the Black-Scholes option pricing model.
	The Company also issues performance-based shares which represent a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, the Company reassesses the probability of the achievement of such corporate performance goals and adjusts expense as necessary.
Segment Information	Segment Information
	The Company operates under one segment which develops pharmaceutical products.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In November 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-16, Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share is More Akin to Debt or to Equity. This update clarifies how current guidance should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. In addition, it clarifies that in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (that is, the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weight those terms and features. The effects of initially adopting the new standard should be applied on a modified retrospective basis to existing hybrid financial instruments issued in a form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted. The Company is currently in the process of evaluating whether the adoption of this update will have a material effect on its condensed consolidated financial statements and related disclosures.
	In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments in this update will require management to assess, at each annual and interim reporting period, the entity’s ability to continue as a going concern and, if management identifies conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued, to disclose in the notes to the entity’s financial statements the principal conditions or events that raised substantial doubt about the entity’s ability to continue as a going concern, management’s evaluation of their significance, and management’s plans that alleviated or are intended to alleviate substantial doubt about the entity’s ability to continue as a going concern. This new standard is effective for annual periods ending after December 15, 2016 and early application is permitted. The Company is currently in the process of evaluating whether the adoption of this update will have a material effect on its condensed consolidated financial statements and related disclosures.
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This pronouncement is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the effect that this pronouncement will have on its financial statements and related disclosures.

Basis_of_Presentation_Tables

Basis of Presentation (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Fair Value Measurements, Recurring and Nonrecurring Assets and Liabilities	The following table presents the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of March 31, 2015 (in thousands):
		Fair Value				Quoted  Market  Prices for Identical Assets			Significant  Other		Significant
						(Level 1)			Observable Inputs		Unobservable
									(Level 2)		Inputs  (Level 3)
	Warrant liability related to February 2015 financing	$	5,213			—			$	—	$	5,213
Summary of Fair Value Measurements, Recurring and Nonrecurring, Valuation Assumptions	The common stock warrant liabilities are recorded at fair value using the Black-Scholes option pricing model.  The following weighted-average assumptions were used in determining the fair value of the common stock warrant liabilities valued using the Black-Scholes option pricing model as of March 31, 2015:
	Risk-free interest rate	1.46		%
	Volatility	132.47		%
	Dividend yield	—		%
	Expected term	6.86 years
	Weighted average fair value	$	1.72
Summary of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table is a reconciliation for all liabilities measured at fair value using Level 3 unobservable inputs (in thousands):
		Warrant liability
	Balance as of December 31, 2014	$	—
	Issuance of warrants in connection with February 2015 financing	5,077
	Change in fair value measurement of warrant liability	136
	Balance as of March 31, 2015	$	5,213
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following securities that could potentially decrease net loss per share in the future are not included in the determination of diluted loss per share as they are anti-dilutive and are as follows:
		Three Months Ended
		March 31,
		2015			2014
	Outstanding stock options	4,592,562			3,684,745
	Outstanding warrants	9,881,659			6,185,492
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The following table presents the weighted average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option-pricing model, as well as the resulting weighted average fair values:
		Three Months Ended
		March 31,
		2015				2014
	Risk-free interest rate	1.39% - 1.67%				1.58% - 1.96%
	Volatility	81.13%- 101.54%				80.75		%
	Dividend yield	—		%		—		%
	Expected term	5.25- 6.08 years				5.25- 6.08 years
	Forfeiture rate	11.54		%		3.6		%
	Weighted average fair value	$	1.05			$	1.48
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan	The following table summarizes the total stock-based compensation expense resulting from share-based awards recorded in the Company’s condensed consolidated statements of operations (in thousands):
		Three Months Ended
		March 31,
		2015				2014
	Research and development	$	30			$	89
	General and administrative	259				402
	Total	$	289			$	491

Other_Financial_Information_Ta

Other Financial Information (Tables)	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Inventory	Inventory is comprised of the following (in thousands):
		March 31,		December 31, 2014
		2015
	Raw materials	$	105	$	106
	Work in process	112		169
	Inventory	$	217	$	275
Accrued Expenses	Accrued expenses are comprised of the following (in thousands):
		March 31,		December 31, 2014
		2015
	Deferred consideration to Forendo (Note 3)	$	2,500	$	2,500
	Outside research and development services	984		838
	Professional fees	991		625
	Deferred compensation	180		176
	Environmental remediation	119		126
	Other	242		290
		$	5,016	$	4,555
Other Long Term Liabilities	Other long term liabilities are comprised of the following (in thousands):
		March 31,		31-Dec-14
		2015
	Deferred compensation	$	268	$	312
	Deferred rent	31		41
	Capital lease payable	3		5
		$	302	$	358

Debt_Tables

Debt (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Summary of Debt	The Company’s notes payable balance consisted of the following (in thousands):
		March 31,			December 31,
		2015			2014
	Notes payable, principal	$	5,000		$	5,000
	Add: accretion of final payment fee	40			16
	Less: unamortized debt discount	(215		)	(237		)
		4,825			4,779
	Less: current portion of notes payable, net	(531		)	(153		)
		$	4,294		$	4,626

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Summary of Warrant Activity	A summary of warrant activity during the three months ended March 31, 2015 is as follows:
		Common Shares		Weighted			Weighted
		Issuable upon		Average			Average
		Exercise		Exercise			Remaining
				Price			Contractual
							Life (in years)
	Outstanding at December 31, 2014	6,859,682		$	3.83		2.7
	Issued	3,021,977		1.82
	Exercised	—		—
	Cancelled	—		—
	Outstanding at March 31, 2015	9,881,659		3.21			3.8
	Exercisable at March 31, 2015	6,859,682		$	3.83		2.4
	The following table shows the number of outstanding warrants by exercise price and date of expiration as of March 31, 2015:
	Shares Issuable Upon Exercise		Exercise Price			Expiration Date
	716,356		$	2.27		Oct-15
	480,392		$	2.55		Dec-15
	2,469,136		$	5.25		Feb-17
	3,000,000		$	3.4		May-18
	3,021,977		$	1.82		Feb-22
	193,798		$	1.29		Jan-24
	9,881,659

Basis_of_Presentation_Addition

Basis of Presentation - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended
	Feb. 28, 2015	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Oct. 17, 2014
		Segment
Basis of Presentation
Retained earnings (accumulated deficit)		$296,264,000		$289,852,000
Net income (loss)		6,412,000	3,262,000
Proceeds from issuance of common stock and warrants, net of issuance cost	10,900,000
Stock and warrant issuance costs	100,000
Number of operating segments		1
Common Stock
Basis of Presentation
Warrants issued (in shares)	3,021,977
Exercise Price	$1.82
Common Stock
Basis of Presentation
Issuance of common stock, net of offering costs (shares)	6,043,955
Loan And Security Agreement
Basis of Presentation
Line of credit facility, maximum borrowing capacity					10,000,000
Loan And Security Agreement | Common Stock
Basis of Presentation
Exercise Price					$1.29
Loan And Security Agreement | Term Loan 2
Basis of Presentation
Line of credit facility, maximum borrowing capacity					$5,000,000

Basis_of_Presentation_Assets_a

Basis of Presentation - Assets and Liabilities Measured on a Recurring Basis, Fair Value (Details) (Fair Value, Measurements, Recurring, USD $)	Mar. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability related to February 2015 financing	$5,213,000
Quoted Market Prices for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability related to February 2015 financing	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability related to February 2015 financing	0
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability related to February 2015 financing	$5,213,000

Basis_of_Presentation_Fair_Val

Basis of Presentation - Fair Value Valuation (Details) (Significant Unobservable Inputs (Level 3), Warrants, USD $)	3 Months Ended
	Mar. 31, 2015
Significant Unobservable Inputs (Level 3) | Warrants
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Risk-free interest rate	1.46%
Volatility	132.47%
Dividend yield	0.00%
Expected term	6 years 10 months 10 days
Weighted average fair value	$1.72

Basis_of_Presentation_Change_i

Basis of Presentation - Change in Level 3 Fair Value (Details) (Warrants, Significant Unobservable Inputs (Level 3), USD $)	3 Months Ended
	Mar. 31, 2015
Warrants | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of December 31, 2014	$0
Issuance of warrants in connection with February 2015 financing	5,077,000
Change in fair value measurement of warrant liability	136,000
Balance as of March 31, 2015	5,213,000
Sensitivity analysis, change in expected volatility rate	150.00%
Sensitivity analysis, increase in liability value	$200,000
Sensitivity analysis, percent increase in liability value	3.40%

Basis_of_Presentation_Stock_Ba

Basis of Presentation - Stock Based Compensation Valuation Assumptions (Details) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Risk-free interest rate, minimum	1.39%	1.58%
Risk-free interest rate, maximum	1.67%	1.96%
Volatility		80.75%
Dividend yield	0.00%	0.00%
Forfeiture rate	11.54%	3.60%
Weighted average fair value	$1.05	$1.48
Shares granted	1.2	1.3
Shares exercised	0.04
Shares Forfeited	0.5
Minimum
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Volatility	81.13%
Expected term	5 years 3 months	5 years 3 months
Maximum
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Volatility	101.54%
Expected term	6 years 0 months 29 days	6 years 0 months 29 days

Basis_of_Presentation_Stock_Ba1

Basis of Presentation - Stock Based Compensation Expense (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$289	$491
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	30	89
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$259	$402

Basis_of_Presentation_Antidilu

Basis of Presentation - Antidilutive Securities (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Outstanding stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of securities that are antidilutive	4,592,562	3,684,745
Outstanding warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of securities that are antidilutive	9,881,659	6,185,492

Vitaros_Licensing_Agreements_A

Vitaros Licensing Agreements - Additional Information (Detail)

3 Months Ended

39 Months Ended

49 Months Ended

39 Months Ended

3 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

17 Months Ended

14 Months Ended

31 Months Ended

75 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Mar. 31, 2015

Dec. 31, 2014

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Dec. 31, 2014

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Feb. 28, 2015

Jan. 31, 2014

Dec. 31, 2013

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Jun. 30, 2014

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

USD ($)

USD ($)

Abbott License Agreement

Bracco License Agreement

Bracco License Agreement

Bracco License Agreement

Sandoz License Agreement

Sandoz License Agreement

Sandoz License Agreement

Sandoz License Agreement

Sandoz License Agreement

Sandoz License Agreement

Sandoz License Amendment Agreement

Sandoz License Amendment Agreement

Sandoz License Amendment Agreement

Sandoz License Amendment Agreement

Sandoz License Amendment Agreement

Majorelle License Agreement

Majorelle License Agreement

Majorelle License Agreement

Majorelle License Agreement

Majorelle License Agreement

Majorelle License Agreement

Majorelle License Agreement

Majorelle License Agreement

Recordati License Agreement

Recordati License Agreement

Recordati License Agreement

Recordati License Agreement

Recordati License Agreement

Takeda Agreement

Takeda Agreement

Actavis plc

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

GERMANY

Sweden and Belgium

Maximum

Maximum

Vitaros

USD ($)

USD ($)

Maximum

Maximum

Vitaros

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Maximum

Maximum

USD ($)

EUR (€)

USD ($)

Maximum

Maximum

Maximum

Maximum

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

Sweden and Belgium

USD ($)

EUR (€)

USD ($)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Proceeds from licensing agreement

$2,500,000

$1,300,000

$3,000,000

$300,000

$1,000,000

$1,000,000

$2,000,000

$200,000

$1,800,000

$2,000,000

$2,500,000

$1,000,000

$2,500,000

Expected upfront license fees and milestone payments

13,200,000

4,900,000

4,500,000

300,000

300,000

36,800,000

33,900,000

2,500,000

Future expected proceeds from sales milestones

13,000,000

47,100,000

45,300,000

41,800,000

18,800,000

16,800,000

15,500,000

38,500,000

37,400,000

34,500,000

36,300,000

33,500,000

Deferred revenue

2,000,000

2,500,000

License revenue

350,000

0

4,300,000

1,000,000

1,000,000

3,000,000

4,000,000

Future expected proceeds from marketing launch milestones

1,500,000

Payments made by Majorelle on behalf of the Company

2,000,000

Future expected proceeds from regulatory milestones

200,000

2,000,000

400,000

400,000

Future expected proceeds from commercial launch payments

$1,100,000

€ 1,000,000

InLicensing_Agreement_Details

In-Licensing Agreement (Details) (USD $)	3 Months Ended		0 Months Ended	1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Oct. 17, 2014	Dec. 31, 2014	Oct. 31, 2014	Feb. 28, 2015	Apr. 30, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accrued license fees	$2,500,000			$2,500,000
Research and development	3,268,000	1,444,000
Forendo License Agreement | Option To Purchase A Drug Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payment of license fees					5,000,000
Maximum product license agreement, regulatory milestone payment			45,000,000
Maximum product license agreement, commercial milestone payment			260,000,000
Research and development				13,600,000
Transaction costs	200,000
Forendo License Agreement | Option To Purchase A Drug Product | Subsequent Event
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accrued license fees							2,500,000
Common Stock
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Issuance of common stock (shares)						6,043,955
Common Stock | Forendo License Agreement | Option To Purchase A Drug Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Issuance of common stock (shares)			3,600,000
Issuance of common stock, value			$5,900,000

Other_Financial_Information_In

Other Financial Information - Inventory (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$105	$106
Work in process	112	169
Inventory	$217	$275

Other_Financial_Information_Ac

Other Financial Information - Accrued Liabilities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Deferred consideration to Forendo (Note 3)	$2,500	$2,500
Outside research and development services	984	838
Professional fees	991	625
Deferred compensation	180	176
Environmental remediation	119	126
Other	242	290
Accrued expenses	$5,016	$4,555

Other_Financial_Information_Ot

Other Financial Information - Other Long-term Liabilities (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Deferred compensation	$268	$312
Deferred rent	31	41
Capital lease payable	3	5
Other long term liabilities	$302	$358

Other_Financial_Information_De

Other Financial Information - (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Deferred compensation, current	$180	$176
Chief Executive Officer And President
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Severance payable period	180 months
Deferred compensation, current	$200	$200

Other_Financial_Information_Ga

Other Financial Information - Gain on Contract Settlement (Details) (USD $)	1 Months Ended	3 Months Ended		12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Gain on contract settlement		$0	$910	$900
Return of common stock in connection with contract settlement (shares)	388,888

Debt_Credit_Agreement_Details

Debt - Credit Agreement (Details) (USD $)	0 Months Ended	3 Months Ended
	Oct. 17, 2014	Mar. 31, 2015	Oct. 17, 2014
Debt Instrument [Line Items]
Number of securities called by warrants (shares)		9,881,659
Loan And Security Agreement
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$10,000,000		$10,000,000
Debt instrument final payment fee, percentage	6.00%
Loan And Security Agreement | Common Stock
Debt Instrument [Line Items]
Number of securities called by warrants (shares)	193,798		193,798
Warrant exercise price (USD per share)	$1.29		$1.29
Loan And Security Agreement | Term Loan 1
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	5,000,000		5,000,000
Interest rate	7.95%		7.95%
Debt instrument, prepayment fee, percentage	3.00%
Interest expense		100,000
Loan And Security Agreement | Term Loan 2
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$5,000,000		$5,000,000

Debt_Term_Loans_Details

Debt - Term Loans (Details) (Loan And Security Agreement, Term Loan 1, USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Loan And Security Agreement | Term Loan 1
Debt Instrument [Line Items]
Notes payable, principal	$5,000,000	$5,000,000
Add: accretion of final payment fee	40,000	16,000
Less: unamortized debt discount	-215,000	-237,000
Long-term Debt	4,825,000	4,779,000
Less: current portion of notes payable, net	-531,000	-153,000
Long-term debt, excluding current maturities	4,294,000	4,626,000
Interest expense	$100,000

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended
	Feb. 28, 2015	Mar. 31, 2015	Dec. 31, 2014
Stockholders Equity Note
Proceeds from issuance of common stock and warrants, net of issuance cost	$10,900,000
Stock and warrant issuance costs	100,000
Shares Issuable Upon Exercise		9,881,659
Warrant liability	$5,100,000	$5,213,000	$0
Common Stock
Stockholders Equity Note
Warrants issued (in shares)	3,021,977
Warrant exercise price (USD per share)	$1.82
Common Stock
Stockholders Equity Note
Issuance of common stock (shares)	6,043,955

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Warrant Activity (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Common shares Issuable upon Exercise
Outstanding at December 31, 2014 (in shares)	6,859,682
Issued (in shares)	3,021,977
Exercised (in shares)	0
Cancelled (in shares)	0
Outstanding as of March 31, 2015 (in shares)	9,881,659	6,859,682
Exercisable at March 31, 2015 (in shares)	6,859,682
Weighted Average Exercise Price
Outstanding at December 31, 2014 (USD per Share)	$3.83
Issued (USD per Share)	$1.82
Exercised (USD per Share)	$0
Cancelled (USD per Share)	$0
Outstanding at March 31, 2015 (USD per Share)	$3.21	$3.83
Exercisable at March 31, 2015 (USD per Share)	$3.83
Weighted Average Contractual Life
Outstanding at December 31, 2014 (in years)		2 years 8 months 6 days
Outstanding at March 31, 2015 (in years)	3 years 9 months 7 days
Exercisable at March 31, 2015 (in years)	2 years 5 months 7 days

Stockholders_Equity_Warrants_O

Stockholders' Equity - Warrants Outstanding by Expiration Date (Details) (USD $)	Mar. 31, 2015	Oct. 17, 2014	Feb. 28, 2015
Class of Warrant or Right [Line Items]
Shares Issuable Upon Exercise	9,881,659
Oct-15
Class of Warrant or Right [Line Items]
Shares Issuable Upon Exercise	716,356
Exercise Price	2.268
Dec-15
Class of Warrant or Right [Line Items]
Shares Issuable Upon Exercise	480,392	480,392
Exercise Price	2.55
Feb-17
Class of Warrant or Right [Line Items]
Shares Issuable Upon Exercise	2,469,136
Exercise Price	5.25
May-18
Class of Warrant or Right [Line Items]
Shares Issuable Upon Exercise	3,000,000
Exercise Price	3.4
Feb-22
Class of Warrant or Right [Line Items]
Shares Issuable Upon Exercise	3,021,977		3,021,977
Exercise Price	1.82		$1.82
Jan-24
Class of Warrant or Right [Line Items]
Shares Issuable Upon Exercise	193,798	193,798
Exercise Price	1.29